Nuclear Medicine and Molecular Imaging

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Comparison of the Results for Sentinel Lymph Node Mapping in the Breast Cancer Patients using $^{99m}Tc$-Antimony Trisulfide Colloid, $^{99m}Tc$-Tin Colloid, and $^{99m}Tc$-Human Serum Albumin

유방암 환자에서 $^{99m}Tc$-Antimony Trisulfide Colloid, $^{99m}Tc$-Tin Colloid, $^{99m}Tc$-Human Serum Albumin을 이용한 감시림프절 매핑 성적의 비교

  • Jang, Sung-June (Research Institute and Hospital, National Cancer Center) ;
  • Moon, Seung-Hwan (Research Institute and Hospital, National Cancer Center) ;
  • Kim, Seok-Ki (Research Institute and Hospital, National Cancer Center) ;
  • Kim, Bom-Sahn (Research Institute and Hospital, National Cancer Center) ;
  • Kim, Seok-Won (Research Institute and Hospital, National Cancer Center) ;
  • Chung, Ki-Wook (Research Institute and Hospital, National Cancer Center) ;
  • Kang, Keon-Wook (Research Institute and Hospital, National Cancer Center) ;
  • Lee, Eun-Sook (Research Institute and Hospital, National Cancer Center)
  • 장성준 (국립암센터 연구소, 부속병원) ;
  • 문승환 (국립암센터 연구소, 부속병원) ;
  • 김석기 (국립암센터 연구소, 부속병원) ;
  • 김범산 (국립암센터 연구소, 부속병원) ;
  • 김석원 (국립암센터 연구소, 부속병원) ;
  • 정기욱 (국립암센터 연구소, 부속병원) ;
  • 강건욱 (국립암센터 연구소, 부속병원) ;
  • 이은숙 (국립암센터 연구소, 부속병원)
  • Published : 2007.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: In the breast cancer patient, lymphatic mapping and sentinel lymph node biopsy are the most important procedure for axillary lymph node staging. We aimed to compare the three radiocolloids [$^{99m}Tc$-antimony trisulfide colloid (ASC), $^{99m}Tc$-tin colloid (TC), and $^{99m}Tc$-human serum albumin (HSA)] for sentinel lymph node mapping. Subjects and Methods: Totally, 397 patients with clinically N0 stage were enrolled. $^{99m}Tc$-ASC was injected in 202 out of 397 patients, $^{99m}Tc$-TC was injected in 120 patients, and $^{99m}Tc$-HSA was injected in the remaining 75 patients. The sentinel lymph nodes were localized by lymphoscintigraphy and selected using intraoperative gamma probe. All sentinel lymph nodes were investigated by intraoperative pathologic consultation. The axillary lymph nodes which were harvested by the lymph node dissection were also investigated. Results: The patients of each group showed similar clinical characteristics. There were no significant differences (p>0.05) in the identification rate of sentinel lymph nodes (IR), false negative rate (FNR), and negative predictive value (NPV). The axillary lymphadenectomy revealed axillary lymph node metastases in those three groups (ASC-33.2%, TC-31.7%, HSA-22.7%). The IR, FNR, and NPV were not significantly different among those groups. Conclusion: Those three $^{99m}Tc$-labeled radiocolloids showed equivalent results in sentinel lymph node mapping of breast cancer.

목적: 유방암 환자에게 불필요한 액와림프절 전절제술을 예방하기 위해서는 감시림프절을 절제하여 전이 여부를 평가하는 것이 중요하다. 감시림프절 매핑을 위한 방사성교질중 antimony trisulfide colloid (ASC), tin colloid (TC), human serum albumin (HSA) 이상의 3가지 교질에 $^{99m}Tc$을 표지하여 각각에서 림포신티그라피, 감시림프절 매핑의 성적을 비교하였다. 대상 및 방법: 2001년 10월부터 2006년 12월까지 임상적으로 액와림프절 전이가 없는 조기 유방암 환자 총 397명에게 시행한 림포신티그라피와 수술 중 감시림프절 절제 동결절편 검사, 및 수술 후 병리 소견을 후향적으로 평가하였다. 림포신티그라피 영상 소견을 분석하고, 감시림프절의 발견율(identification rate)과 위음성율(false negative rate), 그리고 음성예측도(negative predictive value)를 구하여 각 군의 자료에 대해 Fisher 직접확률법으로 비교하였다. 결과: 202명에게는 $^{99m}Tc$ ASC를, 120명에게는 $^{99m}Tc$-TC를, 75명에게는 $^{99m}Tc$-HSA를 사용하였으며 평균 연령, 병기, 원발 종양의 크기 등에서는 각 군별 환자들 사이에 유의한 차이가 없었다. ASE는 59명에게는 유륜부 피내 혹은 피하주사법을 사용했으며 136명에게는 종양주위 주사를, 그리고 7명의 환자에게는 두 가지를 병용하였다. TC와 HSA를 사용한 환자들에게는 모두 피내 혹은 피하주사하였다. 액와림프절 전이는 ASE사용 군에서 33.2%, TC 사용군에서 31.7%, HSA 사용 군에서 22.7%였으며 통계적으로 유의한 차이는 없었다. 감시 림프절 발견율(IR) 과 위음성율(FNR) 그리고 음성예측도(NPV) 는 사용한 교질 ASC/TC/HSA 각각에 대해 99.0%, 21.5%, 90.5% / 96.7%, 20.5%, 90.7% / 94.7%, 17.7%, 94.7%로 사용한 교질의 종류에 따라 통계적으로 유의한 차이가 없었다. 감시림프절 매핑 성적은 방사성교질의 주사방법에 따라서 유의한 차이를 보이지 않았다. 림포신티그라피의 영상에서 감시림프절이 명확히 구분된 경우는 ASC에서 79.6%, TC 에서 92.5%, HSA에서 88.6%였다. 림프관이 관찰된 비율은 ASC에서 43.6%, TC에서 0.8%, HSA 에서 96.8%이었다. 림포신티그라피에서 관찰된 감시림프절의 개수는 HSA가 가장 많았지만 통계적으로 유의한 차이는 없었다. 결론: ASC, TC 및 HSA등의 방사성교질을 이용한 감시림프절 매핑 성적은 서로 유의한 차이를 보이지 않았다.

Keywords

References

  1. Albertini JJ, Lyman GH, Cox C, Yeatman T, Balducci L, Ku N, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818-22 https://doi.org/10.1001/jama.276.22.1818
  2. Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995;222:394-9 https://doi.org/10.1097/00000658-199509000-00016
  3. Copeland EM III. Is axillary dissection necessary for T1 carcinoma of the breast? J Am Coll Surg 1997;184:397-8
  4. Ruffin WK, Stacey-Clear A, Younger J, Hoover HC Jr. Rationale for routine axillary dissection in carcinoma of the breast. J Am Coll Surg 1995;180:245-51
  5. Graversen HP, Blichert‐Toft M, Andersen JA, Zedeler K. Breast cancer: risk of axillary recurrence in node-negative patients following partial dissection of the axilla. Eur J Surg Oncol 1988;14:407-12
  6. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-7 https://doi.org/10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H
  7. NIH Consensus Conference: Treatment of early-stage breast cancer. JAMA 1991;265:391-5 https://doi.org/10.1001/jama.265.3.391
  8. Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gamagami P. Axillary lymph node dissection for T1a breast carcinoma. Is it indicated? Cancer 1994;73:664-7 https://doi.org/10.1002/1097-0142(19940201)73:3<664::AID-CNCR2820730326>3.0.CO;2-S
  9. Boolbol SK, Fey JV, Borgen PI, Heerdt AS, Montgomery LL, Michael Paglia, et al. Intradermal isotope injection: a highly accurate method of lymphatic mapping in breast carcinoma. Ann Surg Oncol 2001;8:20-4 https://doi.org/10.1007/s10434-001-0020-x
  10. Kim BT. Sentinel lymph node imaging in breast cancer. Korean J Nuc Med 1999;33:243-6
  11. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer 1977;39:456-66 https://doi.org/10.1002/1097-0142(197702)39:2<456::AID-CNCR2820390214>3.0.CO;2-I
  12. Morton DL, Thompson JF, Essner R, Elashoff R, Stern SL, Nieweg OE, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999;230:453-63 https://doi.org/10.1097/00000658-199910000-00001
  13. Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, et al. The sentinel node in breast cancer-a multicenter validation study. N Engl J Med 1998;339:941-6 https://doi.org/10.1056/NEJM199810013391401
  14. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391-8 https://doi.org/10.1097/00000658-199409000-00015
  15. Bennett LR, Lago G. Cutaneous lymphoscintigraphy in malignant melanoma. Semin Nucl Med 1983;13:61-9 https://doi.org/10.1016/S0001-2998(83)80037-3
  16. Sadek S, Owunwanne A, Abdel‐Dayem HM, Yacoub T. Preparation and evaluation of Tc-99m hydroxyethyl starch as a potential radiopharmaceutical for lymphoscintigraphy: comparison with Tc-99m human serum albumin, Tc-99m dextran, and Tc-99m sulfur microcolloid. Lymphology 1989;22:157-66
  17. McNeill GC, Witte MH, Witte CL, Williams WH, Hall JN, Patton DD, et al. Whole-body lymphangioscintigraphy: preferred method for initial assessment of the peripheral lymphatic system. Radiology 1989;172:495-502 https://doi.org/10.1148/radiology.172.2.2748831
  18. Kataoka M, Kawamura M, Hamada K, Itoh H, Nishiyama Y, Hamamoto K. Quantitative lymphoscintigraphy using 99m-Tc human serum albumin in patients with previously treated uterine cancer. Br J Radiol 1991;64:1119-21 https://doi.org/10.1259/0007-1285-64-768-1119
  19. Alavi A, Staum MM, Shesol BF, Bloch PH. Technetium-99m stannous phytate as an imaging agent for lymph nodes. J Nucl Med 1978;19:422-6
  20. Hung JC, Wiseman GA, Wahner HW, Mullan BP, Taggart TR, Dunn WL. Filtered technetium-99m-sulfur colloid evaluated for lymphoscintigraphy. J Nucl Med 1995;36:1895-901
  21. Strand SE, Persson BR. Quantitative lymphoscintigraphy I: Basic concepts for optimal uptake of radiocolloids in the parasternal lymph nodes of rabbits. J Nucl Med 1997;20:1038-46
  22. Alazraki NP, Eshima D, Eshima LA, Herda SC, Murray DR, Vansant JP, et al. Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer, and other potential cancers. Semin Nucl Med 1997;27:55-67 https://doi.org/10.1016/S0001-2998(97)80036-0
  23. Saha GP, Feiglin DHI, O'Donnel JK, Go RT, Karam PM, Maclntyre W. Experience with technetium-99m albumin colloid kit for reticuloendothelial system imaging. J Nucl Med Technol 1986;14:149-51
  24. Pijper R, Meijer S, Hoekstra OS, Collet GJ, Comans EFI, Boom RPA, et al. Impact of lymphoscintigraphy on sentinel node identification with technetium-99m-colloidal albumin in breast cancer. J Nucl Med 1997;38:366-8
  25. Mariani G, Erba P, Villa G, Gipponi M, Manca G, Boni G, et al. Lymphoscintigraphic and intraoperative detection of the sentinel lymph node in breast cancer patients: the nuclear medicine perspective. J Surg Oncol 2004;85:112-22 https://doi.org/10.1002/jso.20023
  26. Wilhelm AJ, Mijnhout GS, Franssen EJ. Radiopharmaceuticals in sentinel lymph‐node detection-an overview. Eur J Nucl Med 1999;26:S36-42 https://doi.org/10.1007/PL00014793
  27. Linehan DC, Hill AD, Tran KN, Yeung H, Yeh SD, Borgen PI, et al. Sentinel lymph node biopsy in breast cancer: unfiltered radioisotope is superior to filtered. J Am Coll Surg 1999;188: 377-81 https://doi.org/10.1016/S1072-7515(98)00314-7
  28. Cody HS 3rd, Borgen PI. State-of-the-art approaches to sentinel node biopsy for breast cancer: study design, patient selection, technique, and quality control at Memorial Sloan-Kettering Cancer Center. Surg Oncol 1999;8:85-91 https://doi.org/10.1016/S0960-7404(99)00029-8
  29. De Cicco C, Chinol M, Paganelli G. Intraoperative localization of the sentinel node in breast cancer: technical aspects of lymphoscintigraphic methods. Semin Surg Oncol 1998;15:268-71 https://doi.org/10.1002/(SICI)1098-2388(199812)15:4<268::AID-SSU16>3.0.CO;2-I